“[T]he impacts of recreational cannabis legalization on psychiatric and psychosocial outcomes are otherwise minimal,” researchers concluded.
The use of cannabis products was associated with “statistically significant improvements in IBD-specific outcomes” at three months.
Compared to those residing in legal states, residents in states were marijuana was illegal “reported a significantly greater number of days driving under the influence of cannabis.”
Investigators concluded, “All patient-reported outcomes showed a statistically significant improvement at 3 months, which was maintained or further improved over the remainder of the 12-month follow-up.”
“[The] patient’s behavior rapidly improved” following THC treatment and he was eventually discharged from in-patient treatment to home care.
According to conclusions provided by the Drug Enforcement Administration, “In US markets, Mexican marijuana has largely been supplanted by domestic-produced marijuana.”
Patients in the treatment group experienced a decrease in pain of 29 percent over the course of the trial, whereas those in the control group only experienced a six percent decrease.
“Medicinal cannabis was associated with improvements in depression and anxiety symptoms, as well as health-related quality of life,” investigators concluded.